Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than ' million visitors each month.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Search artcles published since 2007

July 26, 2012--------News Archive Return to: News Alerts


The FDA evaluation of Truvada relied heavily on two large studies.
One was a UCSF-led study of men and transgender women who have sex with men,
which found that Truvada reduced risk of infection by 42 percent.
The second, Partners PrEP, was a study in Africa of HIV transmission in
heterosexual couples. Researchers found that risk was reduced by 75 percent.

WHO Child Growth Charts

       

HIV/AIDS Prevention with Truvada: How Pregnant Women and Others May Benefit

Infection with AIDS virus need not spread to uninfected partners

Truvada this week became the first drug approved by the U.S. Food and Drug Administration (FDA) for the prevention of HIV infection and AIDS in individuals at “high risk.”

The FDA evaluation relied heavily on two large studies. One was a UCSF-led study of men and transgender women who have sex with men, which found that Truvada reduced risk of infection by 42 percent. The second, Partners PrEP, was a study in Africa of HIV transmission in heterosexual couples. Researchers found that risk was reduced by 75 percent.

Apart from the specific populations studied in these large-scale trials, others deemed to be at high risk can also lower their chances of becoming infected. For instance, Deborah Cohan, MD, MPH, a UCSF obstetrician and gynecologist who specializes in the care of pregnant women with HIV, has been evaluating the use of Truvada in pregnant women in the U.S. who are uninfected, but whose male partners have HIV.


“There is a growing body of evidence to suggest that pregnancy increases the risk of HIV acquisition.”

Deborah Cohan, MD, MPH


Additional large studies, including FEM-PrEP and TDF2, also have shed light on Truvada use in women. “The data that support its use for women are for resource-limited settings outside the U.S.,” Cohan said. “One of the things that was clear … is that adherence to the treatment is key, and that perception of risk probably drives adherence.”

Testing Pre-Exposure Prophylaxis (PrEP)
Cohan is expanding this research, creating a multi-center collaborative project to study the treatment approach, called pre-exposure prophylaxis (PrEP), in uninfected women who intend to become pregnant. Cohan runs the UCSF Perinatal HIV Clinic as part of the Women's HIV Program at UCSF and is medical director of the Bay Area Perinatal AIDS Center (BAPAC) at San Francisco General Hospital and Trauma Center.

Cohan:“Now that there is FDA approval we want to try to identify optimal candidates for this intervention, and to understand how to optimize adherence to prescribed therapy. This includes understanding peoples’ perception of risk.”

An individual’s risk of infection — and how much taking a daily Truvada pill may reduce it — depends on several factors, such as the precautions sexual partners already may be taking.


Research has made it clear,
when HIV-infected individuals lower levels of virus
in their blood by taking antiretroviral therapy, they not
only prevent progression of HIV-associated disease,
they also greatly reduce the risk of transmitting
the virus to their sexual partners.


Among heterosexual couples, if HIV levels in the HIV-positive partner remain suppressed with antiviral therapy, the risk of HIV transmission to the uninfected partner appears to be especially small. “It’s officially not zero, because we know of at least one case report,” Cohan said.

In addition, condom use is effective in preventing the spread of HIV, and avoiding the sharing of needles is an effective strategy for preventing the spread of HIV that stems from injection drug use.

Of course, couples trying to conceive do not use condoms, and keeping viral loads low in HIV-infected individuals requires reliable adherence to antiretroviral therapy, Cohan said. The U.S. Centers for Disease Control and Prevention last year estimated that barely one-in-four HIV-infected individuals in the U.S. has achieved viral suppression, which the agency defined as the presence in the blood of 200 or fewer copies of the virus per milliliter.

HIV-Negative Partner May Gain Control to Remain Uninfected
“Just relying on HIV-positive partners taking their medications and being virally suppressed does not guarantee that they’re not going to transmit HIV to their HIV-negative partners,” Cohan said.

She continues: “What we do for pregnant women who are on PrEP is to try to get their male partners onto antiretrovirals if they are not yet on them. We ask that their partners’ providers obtain monthly measures of viral loads to make sure they are suppressed. That’s not standard practice. Usually people may get viral loads every three months, or even less often if they have been suppressed for a while.

“I think that this gives control to the negative partner to keep herself HIV-negative.”

When blood tests indicate that one partner is HIV-positive and the other is HIV-negative, the couple may be described as “serodiscordant.”

Cohan: “Many of the women I know who are in serodiscordant relationships are in excellent communication with their partners, and their partners’ providers are in excellent communication with us.

“But probably more frequently the woman doesn’t necessarily know whether her partner is taking antiretrovirals regularly, or how often he is having viral loads checked. In many cases his HIV provider may not even know that he is sexually active with an HIV-negative woman.”

Who Will Prescribe Truvada?
Sorting out how individuals who can lower their infection risk with PrEP will be able to pay for Truvada is one question on the minds of many, but there are additional issues when it comes to getting Truvada into the hands of patients, Cohan said.

Cohan: “Many HIV clinics are not set up to take care of HIV-negative individuals. They may be reimbursed for the numbers of encounters that they have with HIV-positive patients. Many of them are not prepared to care for and to be reimbursed for caring for HIV-negative people.

“On the flip side, most OBGYN clinics and most general practice clinics that don’t provide HIV care, per se, don’t feel equipped to prescribe Truvada for HIV-negative women in serodiscordant relationships.

“From my standpoint it’s relatively straightforward — there are going to be protocols established. Still, it’s unfamiliar. At most places they are not comfortable prescribing antiretrovirals if it’s not an HIV clinic.”

Original article: http://www.ucsf.edu/news/2012/07/12377/hiv-aids-prevention-truvada-how-pregnant-women-and-others-may-benefit